Loading…
Protara Therapeutics, Inc. is projected to rise to $5.58 by 2027, a +33% move from its current price of $4.20. TARA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.07 | $4.20 | $4.34 | +0.06% |
| Jul 14 | $4.02 | $4.21 | $4.40 | +0.13% |
| Jul 15 | $3.98 | $4.21 | $4.45 | +0.19% |
| Jul 16 | $3.95 | $4.21 | $4.49 | +0.26% |
| Jul 17 | $3.93 | $4.21 | $4.52 | +0.32% |
| Jul 18 | $3.90 | $4.22 | $4.56 | +0.39% |
| Jul 19 | $3.88 | $4.22 | $4.59 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.88 | $4.22 | $4.59 | +0.45% |
| Week 2 | $3.76 | $4.24 | $4.77 | +0.90% |
| Week 3 | $3.68 | $4.26 | $4.92 | +1.35% |
| Week 4 | $3.62 | $4.28 | $5.06 | +1.81% |
| Week 5 | $3.56 | $4.30 | $5.18 | +2.27% |
| Week 6 | $3.51 | $4.31 | $5.30 | +2.73% |
| Week 7 | $3.47 | $4.33 | $5.41 | +3.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protara Therapeutics, Inc. is a Healthcare sector clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy that is in Phase II trials for non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Protara Therapeutics trades under the symbol TARA and operates within the healthcare field, pursuing transformative therapies that address cancer and rare diseases. The stock is currently tracked with a market capitalization in the mid-range and a position in the market ranking system, reflecting its size and focus within biotech development.
Protara Therapeutics, Inc. (TARA) is a clinical-stage biopharmaceutical company in the Healthcare sector. The current price is $4.07 and the market cap is $228.75M, with a market-rank of 3735.
The 30-day technical picture shows near-term pressure with bearish sentiment, while the forecast indicates a long-term bullish trajectory with rising averages and ROIs through 2050.
Near-term dynamics show a neutral start in 2026 (avg $4.07, min $3.65, max $5.76; ROI 0) before a bullish runway emerges in subsequent years, with higher expected averages and ROIs through 2030 and beyond. The multi-year outlook points to meaningful upside potential, culminating in a 2050 average price of $25.23 and a ROI of 519.9%, though this comes with acknowledged uncertainty and variability in outcomes.
A major floor 25.2% below — a decisive break under it would weaken the trend.
The nearest floor, 13.1% below — buyers have tended to step in here.
The nearest ceiling, 13.1% above — a clean break opens room to run.
A major ceiling 47.6% above — clearing it would confirm fresh momentum.
Key TARA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TARA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.20 | Buy | $4.20 | Sell |
| MA 10 | $4.12 | Buy | $4.15 | Buy |
| MA 20 | $4.03 | Buy | $4.15 | Buy |
| MA 50 | $4.51 | Sell | $4.44 | Sell |
| MA 100 | $5.02 | Sell | $4.78 | Sell |
| MA 200 | $5.33 | Sell | $4.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.43 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 163.04 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 8.00 | Buy |
| Bollinger %B (20,2) | 0.96 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.45 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 69.79 | Neutral |
| Momentum (10) | 0.32 | Buy |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 4.26 | Sell |
| ADX (14) | 14.19 | Neutral |
| ATR (14) | 0.13 | Info |
Technical snapshot (30 days): sentiment is BEARISH, with RSI(14) at 40. The 50-day moving average sits at $4.85 and the 200-day moving average at $5.26. Near-term support is listed at $3.65 and resistance at $5.66. The 30-day price range spans from $3.24 to $5.12, indicating a sideways-to-downward tilt in the near term until a clear breakout occurs.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.65 | $4.20 | $5.79 | 0% | Neutral | |
| $4.37 | $5.58 | $7.56 | +33% | Bullish | |
| $4.69 | $6.18 | $8.73 | +47% | Bullish | |
| $5.05 | $6.84 | $9.99 | +63% | Bullish | |
| $4.74 | $6.57 | $9.87 | +57% | Bullish | |
| $4.90 | $6.95 | $10.69 | +65% | Bullish | |
| $5.32 | $7.71 | $12.12 | +84% | Bullish | |
| $5.52 | $8.16 | $13.07 | +94% | Bullish | |
| $6.71 | $10.09 | $16.46 | +140% | Bullish | |
| $7.40 | $11.35 | $18.80 | +170% | Bullish | |
| $8.80 | $14.64 | $25.98 | +249% | Bullish | |
| $14.94 | $28.71 | $56.25 | +584% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.65 | $4.20 | $5.01 | +0.00% |
| August 2026 | $3.65 | $4.33 | $5.29 | +3.11% |
| September 2026 | $3.73 | $4.45 | $5.51 | +2.82% |
| October 2026 | $3.61 | $4.34 | $5.43 | -2.45% |
| November 2026 | $3.58 | $4.33 | $5.46 | -0.24% |
| December 2026 | $3.74 | $4.56 | $5.79 | +5.12% |
Click any year to see its month-by-month TARA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TARA price prediction for 2026 points to an average of $4.20 (low $3.65, high $5.79) — a potential gain of 0% on today's $4.20. A consolidation phase looks the most probable path here.
In 2027, TARA is projected to trade between $4.37 and $7.56, averaging $5.58 — a potential gain of +33% from today's $4.20. That is up +33% on the projected 2026 average. Momentum favours further upside here.
Protara Therapeutics, Inc.'s 2028 outlook centres on $6.18, within a $4.69 to $8.73 range. That is up +11% on the projected 2027 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, TARA could reach as high as $9.99, with a base case around $6.84 and support toward $5.05 — roughly +63% from $4.20. Momentum favours further upside here.
Expect TARA to range from $4.74 to $9.87 through 2030. The $6.57 average target implies a +57% move from current prices. That is -4% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The TARA price prediction for 2031 points to an average of $6.95 (low $4.90, high $10.69) — a potential gain of +65% on today's $4.20. Momentum favours further upside here.
In 2032, TARA is projected to trade between $5.32 and $12.12, averaging $7.71 — a potential gain of +84% from today's $4.20. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Protara Therapeutics, Inc.'s 2033 outlook centres on $8.16, within a $5.52 to $13.07 range. That is up +6% on the projected 2032 average. That marks a +94% change versus current levels. Momentum favours further upside here.
By 2034, TARA could reach as high as $16.46, with a base case around $10.09 and support toward $6.71 — roughly +140% from $4.20. Buyers look set to stay in control over this stretch.
Expect TARA to range from $7.40 to $18.80 through 2035. The $11.35 average target implies a +170% move from current prices. That is up +12% on the projected 2034 average. Momentum favours further upside here.
The TARA price prediction for 2040 points to an average of $14.64 (low $8.80, high $25.98) — a potential gain of +249% on today's $4.20. Buyers look set to stay in control over this stretch.
In 2050, TARA is projected to trade between $14.94 and $56.25, averaging $28.71 — a potential gain of +584% from today's $4.20. That is up +96% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in TARA today (≈ 238.095238 TARA) could be worth
$6,835.47
+$5,835.47 (+584%) by 2050 · US Dollar
Based on the average projected TARA price of $28.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TARAwould be worth at today's price.
$1,000 invested in TARA on Jul 10, 2025 (≈ 320.512832 TARA) would be worth
$1,346.15
+$346.15 (+34.6%) today · 1.35× · US Dollar
Based on a TARA entry price of $3.12 vs. today's $4.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.06 | $1,034.48 | +3.4% |
| 1 month ago | $3.78 | $1,111.11 | +11.1% |
| 3 months ago | $4.96 | $846.77 | -15.3% |
| 6 months ago | $5.24 | $801.53 | -19.8% |
| 1 year ago | $3.12 | $1,346.15 | +34.6% |
| All time (5.0y) ago | $8.83 | $475.65 | -52.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TARA forecast.
Our base-case forecast reaches $8.40 around 2034.
Implied market cap at $8.40: $472.12M
The multi-year forecast shows a bullish trajectory after 2026, with rising averages and ROIs across successive years. In 2026, the min, avg, and max are $3.65, $4.07, and $5.76, respectively, with ROI 0% and a Neutral sentiment. By 2027 the avg climbs to $5.36 with ROI 31.6%, and it further strengthens through 2028 ($6.00, ROI 47.4%), 2029 ($6.51, ROI 59.9%), and 2030 ($6.06, ROI 48.9%).
The bull run continues with 2031 ($6.58, ROI 61.7%), 2032 ($7.10, ROI 74.4%), and 2033 ($7.16, ROI 76%). The forecast accelerates in later years: 2034 avg $9.49, ROI 133.3%; 2035 avg $10.57, ROI 159.6%. The long-term horizon shows substantial upside with 2040 avg $13.34, ROI 227.9%, and 2050 avg $25.23, ROI 519.9%.
These figures imply meaningful upside potential but remain estimates, not guarantees, and subject to market and development risks.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $6.06, with a min of $4.27 and a max of $9.31; ROI 48.9%; sentiment bullish.
The forecast turns bullish from 2027 onward with rising averages and ROIs (e.g., 2027 avg $5.36, ROI 31.6%; 2028 avg $6.00, ROI 47.4%; 2029 avg $6.51, ROI 59.9%; 2030 avg $6.06, ROI 48.9%). The near term (2026) is neutral with avg $4.07 and ROI 0%.
Yes. The 2033 forecast lists a max of $11.79, with an avg of $7.16 and a min of $4.71, and a bullish sentiment.
For 2040, the forecast shows min $7.67, avg $13.34, max $24.49, with ROI 227.9% and bullish sentiment.
For 2050, the forecast shows min $12.27, avg $25.23, max $51.40, with ROI 519.9% and bullish sentiment.
Protara Therapeutics, Inc. Community Discussion
0Share your Protara Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.